Similar to the other six independent breast cancer datasets, in GSE22226, even with standard neoadjuvant treatment, patients with a high level expression of MCM10 had a significantly shorter survival time compared to those with a low level expression of MCM10 (p = 0.013; Figure 7D). The gene discussed is MCM10; the disease is breast carcinoma.